To our community: Due to circumstances surrounding COVID-19, Clinical Research IO had to make the difficult decision to discontinue funding for Caretalk. We've decided to leave the website up as a resource for the community. Thank you so much to everyone who made this possible, and please enjoy!

Efficacy and Safety of Semaglutide 2.0 mg s.c. Once-weekly Compared to Semaglutide 1.0 mg s.c. Once-weekly in Subjects With Type 2 Diabetes

SPONSORED BY Novo Nordisk

Clinical Study Identifier: nn9535-4506

Caretalk keeps your information private.

To help you apply, Caretalk securely shares only the information you enter in this form with the researchers conducting this study. See our Privacy Policy for more information.

Even if you don't qualify to be a part of this particular study, please check back - there are many new studies each day who need people like you!

Similar Clinical Trials

Trial Sponsor Location Status Start Date Follow
timi58-declare Astrazeneca Pharmaceuticals Enrolling
A Randomized, 26-week, Open-label, 2-treatment Arm, Parallel Group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua™) Titrated Using a Simple Titration Algorithm (One Unit Daily Adjustment) Compared With Insulin Glargine/Lixisenatide Fixed-ratio Combination (Soliqua™) Titrated by Weekly Adjustment in Patients With Type 2 Diabetes Mellitus (T2DM) Sanofi Pasteur, Inc. Enrolling 3/11/2019
Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease Novo Nordisk Enrolling 6/17/2019